keyword
MENU ▼
Read by QxMD icon Read
search

immunogenicity vaccine

keyword
https://www.readbyqxmd.com/read/29223801/the-external-face-of-candida-albicans-a-proteomic-view-of-the-cell-surface-and-the-extracellular-environment
#1
Ana Gil-Bona, Ahinara Amador-García, Concha Gil, Lucia Monteoliva
The cell surface and secreted proteins are the initial points of contact between Candida albicans and the host. Improvements in protein extraction approaches and mass spectrometers have allowed researchers to obtain a comprehensive knowledge of these external subproteomes. In this paper, we review the published proteomic studies that have examined C. albicans extracellular proteins, including the cell surface proteins or surfome and the secreted proteins or secretome. The use of different approaches to isolate cell wall and cell surface proteins, such as fractionation approaches or cell shaving, have resulted in different outcomes...
December 6, 2017: Journal of Proteomics
https://www.readbyqxmd.com/read/29223454/preparation-characterization-and-immunological-evaluation-of-alginate-nanoparticles-loaded-with-whole-inactivated-influenza-virus-dry-powder-formulation-for-nasal-immunization-in-rabbits
#2
Solmaz Dehghan, Masoumeh Tavassoti Kheiri, Khalil Abnous, Maryam Eskandari, Mohsen Tafaghodi
It has become important to explore more efficient and feasible influenza vaccines, since epidemics of influenza virus cause hundreds of thousands of deaths all around the world. Improving immunogenicity of parentral influenza vaccines has given rise to mucosal delivery routes. In this study, alginate nanoparticles (NPs) were efficiently synthetized by ionic gelation method and influenza virus and CpG ODN or Quillaja Saponin (QS) adjuvants were actively incorporated into alginate NPs. The prepared particles were evaluated for both humoral and cellular immune responses in rabbits' nostrils...
December 6, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/29223138/plant-expressed-fc-fusion-protein-tetravalent-dengue-vaccine-with-inherent-adjuvant-properties
#3
Mi Young Kim, Alastair Copland, Kaustuv Nayak, Anmol Chandele, Muhammad Shamsher Ahmed, Qibo Zhang, Gil Reynolds Diogo, Matthew John Paul, Sven Hofmann, Moon-Sik Yang, Yong-Suk Jang, Julian K-C Ma, Rajko Reljic
Dengue is a major global disease requiring improved treatment and prevention strategies. The recently licensed Sanofi-Pasteur Denvaxia vaccine does not protect children under the age of nine and additional vaccine strategies are thus needed to halt this expanding global epidemic. Here, we employed a molecular engineering approach and plant-expression to produce a humanised and highly immunogenic Poly-Immunoglobulin G Scaffold (PIGS) fused to the consensus dengue envelope protein III domain (cEDIII). The immunogenicity of this IgG Fc receptor targeted vaccine candidate was demonstrated in transgenic mice expressing human FcγRI/CD64, by induction of neutralising antibodies and evidence of cell-mediated immunity...
December 9, 2017: Plant Biotechnology Journal
https://www.readbyqxmd.com/read/29222332/stabilization-of-the-gp120-v3-loop-through-hydrophobic-interactions-reduces-the-immunodominant-v3-directed-non-neutralizing-response-to-hiv-1-envelope-trimers
#4
Steven W de Taeye, Alba Torrents de la Peña, Andrea Vecchione, Enzo Scutigliani, Kwinten Sliepen, Judith A Burger, Patricia van der Woude, Anna Schorcht, Edith E Schermer, Marit J van Gils, Celia C LaBranche, David C Montefiori, Ian A Wilson, John P Moore, Andrew B Ward, Rogier W Sanders
To provide protective immunity against circulating primary HIV-1 strains, a vaccine most likely has to induce broadly neutralizing antibodies (bNAbs) to the HIV-1 envelope (Env) glycoprotein spike. Recombinant Env trimers such as the prototype BG505 SOSIP.664 that closely mimic the native Env spike can induce autologous neutralizing antibodies (NAbs) against relatively resistant (tier-2) primary viruses. Ideally, Env immunogens should present bNAb epitopes, but limit the presentation of immunodominant non-NAb epitopes that might induce off-target and potentially interfering responses...
December 8, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29218997/causes-of-impaired-oral-vaccine-efficacy-in-developing-countries
#5
Edward Pk Parker, Sasirekha Ramani, Benjamin A Lopman, James A Church, Miren Iturriza-Gómara, Andrew J Prendergast, Nicholas C Grassly
Oral vaccines are less immunogenic when given to infants in low-income compared with high-income countries, limiting their potential public health impact. Here, we review factors that might contribute to this phenomenon, including transplacental antibodies, breastfeeding, histo blood group antigens, enteric pathogens, malnutrition, microbiota dysbiosis and environmental enteropathy. We highlight several clear risk factors for vaccine failure, such as the inhibitory effect of enteroviruses on oral poliovirus vaccine...
December 8, 2017: Future Microbiology
https://www.readbyqxmd.com/read/29217376/safety-tolerability-and-immunogenicity-of-two-zika-virus-dna-vaccine-candidates-in-healthy-adults-randomised-open-label-phase-1-clinical-trials
#6
Martin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, Zonghui Hu, Galina Yamshchikov, Ro Shauna Rothwell, Nina Berkowitz, Floreliz Mendoza, Jamie G Saunders, Laura Novik, Cynthia S Hendel, LaSonji A Holman, Ingelise J Gordon, Josephine H Cox, Srilatha Edupuganti, Monica A McArthur, Nadine G Rouphael, Kirsten E Lyke, Ginny E Cummings, Sandra Sitar, Robert T Bailer, Bryant M Foreman, Katherine Burgomaster, Rebecca S Pelc, David N Gordon, Christina R DeMaso, Kimberly A Dowd, Carolyn Laurencot, Richard M Schwartz, John R Mascola, Barney S Graham, Theodore C Pierson, Julie E Ledgerwood, Grace L Chen
BACKGROUND: The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane and envelope Zika virus structural proteins. METHODS: We did two phase 1, randomised, open-label trials involving healthy adult volunteers. The VRC 319 trial, done in three centres, assessed plasmid VRC5288 (Zika virus and Japanese encephalitis virus chimera), and the VRC 320, done in one centre, assessed plasmid VRC5283 (wild-type Zika virus)...
December 4, 2017: Lancet
https://www.readbyqxmd.com/read/29217375/preliminary-aggregate-safety-and-immunogenicity-results-from-three-trials-of-a-purified-inactivated-zika-virus-vaccine-candidate-phase-1-randomised-double-blind-placebo-controlled-clinical-trials
#7
Kayvon Modjarrad, Leyi Lin, Sarah L George, Kathryn E Stephenson, Kenneth H Eckels, Rafael A De La Barrera, Richard G Jarman, Erica Sondergaard, Janice Tennant, Jessica L Ansel, Kristin Mills, Michael Koren, Merlin L Robb, Jill Barrett, Jason Thompson, Alison E Kosel, Peter Dawson, Andrew Hale, C Sabrina Tan, Stephen R Walsh, Keith E Meyer, James Brien, Trevor A Crowell, Azra Blazevic, Karla Mosby, Rafael A Larocca, Peter Abbink, Michael Boyd, Christine A Bricault, Michael S Seaman, Anne Basil, Melissa Walsh, Veronica Tonwe, Daniel F Hoft, Stephen J Thomas, Dan H Barouch, Nelson L Michael
BACKGROUND: A safe, effective, and rapidly scalable vaccine against Zika virus infection is needed. We developed a purified formalin-inactivated Zika virus vaccine (ZPIV) candidate that showed protection in mice and non-human primates against viraemia after Zika virus challenge. Here we present the preliminary results in human beings. METHODS: We did three phase 1, placebo-controlled, double-blind trials of ZPIV with aluminium hydroxide adjuvant. In all three studies, healthy adults were randomly assigned by a computer-generated list to receive 5 μg ZPIV or saline placebo, in a ratio of 4:1 at Walter Reed Army Institute of Research, Silver Spring, MD, USA, or of 5:1 at Saint Louis University, Saint Louis, MO, USA, and Beth Israel Deaconess Medical Center, Boston, MA, USA...
December 4, 2017: Lancet
https://www.readbyqxmd.com/read/29217369/influence-of-the-intestinal-microbiota-on-the-immunogenicity-of-oral-rotavirus-vaccine-given-to-infants-in-south-india
#8
Edward P K Parker, Ira Praharaj, Anna Zekavati, Robin P Lazarus, Sidhartha Giri, Darwin J Operario, Jie Liu, Eric Houpt, Miren Iturriza-Gómara, Beate Kampmann, Jacob John, Gagandeep Kang, Nicholas C Grassly
Oral rotavirus vaccines have consistently proven to be less immunogenic among infants in developing countries. Discrepancies in the intestinal microbiota, including a greater burden of enteropathogens and an altered commensal community composition, may contribute to this trend by inhibiting the replication of vaccine viruses. To test this possibility, we performed a nested case-control study in Vellore, India, in which we compared the intestinal microbiota of infants who responded serologically or not after two doses of Rotarix delivered at 6 and 10 weeks of age as part of a clinical trial (CTRI/2012/05/002677)...
December 4, 2017: Vaccine
https://www.readbyqxmd.com/read/29216187/a-thermostable-messenger-rna-based-vaccine-against-rabies
#9
Lothar Stitz, Annette Vogel, Margit Schnee, Daniel Voss, Susanne Rauch, Thorsten Mutzke, Thomas Ketterer, Thomas Kramps, Benjamin Petsch
Although effective rabies virus vaccines have been existing for decades, each year, rabies virus infections still cause around 50.000 fatalities worldwide. Most of these cases occur in developing countries, where these vaccines are not available. The reasons for this are the prohibitive high costs of cell culture or egg grown rabies virus vaccines and the lack of a functional cold chain in many regions in which rabies virus is endemic. Here, we describe the excellent temperature resistance of a non-replicating mRNA based rabies virus vaccine encoding the rabies virus glycoprotein (RABV-G)...
December 7, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29213269/safety-and-immunogenicity-of-malaria-vectored-vaccines-given-with-routine-expanded-program-on-immunization-vaccines-in-gambian-infants-and-neonates-a-randomized-controlled-trial
#10
Victorine A Mensah, Sophie Roetynck, Ebrima K Kanteh, Georgina Bowyer, Amy Ndaw, Francis Oko, Carly M Bliss, Ya Jankey Jagne, Riccardo Cortese, Alfredo Nicosia, Rachel Roberts, Flavia D'Alessio, Odile Leroy, Babacar Faye, Beate Kampmann, Badara Cisse, Kalifa Bojang, Stephen Gerry, Nicola K Viebig, Alison M Lawrie, Ed Clarke, Egeruan B Imoukhuede, Katie J Ewer, Adrian V S Hill, Muhammed O Afolabi
Background: Heterologous prime-boost vaccination with chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) encoding multiple epitope string thrombospondin-related adhesion protein (ME-TRAP) has shown acceptable safety and promising immunogenicity in African adult and pediatric populations. If licensed, this vaccine could be given to infants receiving routine childhood immunizations. We therefore evaluated responses to ChAd63 MVA ME-TRAP when co-administered with routine Expanded Program on Immunization (EPI) vaccines...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29212932/minor-capsid-protein-l2-polytope-induces-broad-protection-against-oncogenic-and-mucosal-human-papillomaviruses
#11
Somayeh Pouyanfard, Gloria Spagnoli, Lorenzo Bulli, Kathrin Balz, Fan Yang, Caroline Odenwald, Hanna Seitz, Filipe C Mariz, Angelo Bolchi, Simone Ottonello, Martin Müller
The amino terminus of the human papillomavirus minor capsid protein L2 contains a major cross-neutralization epitope which provides the basis for the development of a broadly protecting HPV vaccine. Wide range of protection against different HPV types would eliminate one of the major drawbacks of the commercial, L1 based prophylactic vaccines. Previously, we have reported that insertion of the L2 epitope into a scaffold composed of bacterial thioredoxin protein generates a potent antigen inducing comprehensive protection against different animal and human papillomaviruses...
December 6, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29209567/dendritic-cells-pulsed-with-tumor-cells-killed-by-high-hydrostatic-pressure-inhibit-prostate-tumor-growth-in-tramp-mice
#12
Romana Mikyskova, Marie Indrova, Ivan Stepanek, Ivan Kanchev, Jana Bieblova, Sarka Vosahlikova, Irena Moserova, Iva Truxova, Jitka Fucikova, Jirina Bartunkova, Radek Spisek, Radislav Sedlacek, Milan Reinis
Dendritic cell (DC)-based vaccines pulsed with high hydrostatic pressure (HHP)-inactivated tumor cells have recently been shown to be a promising tool for prostate cancer chemoimmunotherapy. In this study, DC-based vaccines, both pulsed and unpulsed, were as effective as docetaxel (DTX) in reducing prostate tumors in the orthotopic transgenic adenocarcinoma of the mouse prostate (TRAMP) model. However, we did not observe any additive or synergic effects of chemoimmunotherapy on the tumor growth, while only the combination of DTX and pulsed dendritic cells resulted in significantly lower proliferation detected by Ki67 staining in histological samples...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29209562/collagen-i-enhances-the-efficiency-and-anti-tumor-activity-of-dendritic-tumor-fusion-cells
#13
Jian He, Rong Zheng, Zhenghua Zhang, Jie Tan, Chaofan Zhou, Guoqing Zhang, Xinglu Jiang, Qianyi Sun, Sufang Zhou, Duo Zheng, Yong Huang, Lige Wu, Zongqiang Lai, Jieping Li, Nuo Yang, Xiaoling Lu, Yongxiang Zhao
Low fusion efficiency and nominal activity of fusion cells (FCs) restrict the clinical application of dendritic cell (DC)/tumor fusion cells. Collagen I (Col I) is an interstitial collagen with a closely-knit structure used to repair damaged cell membranes. This study evaluated whether Col I could improve the fusion efficiency of polyethylene glycol (PEG)-induction and enhance the immunogenicity of fusion vaccine. DC/B16 melanoma and controlled DC/H22 hepatoma cell fusions were induced by PEG with or without Col I...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29207661/immunization-with-recombinant-rabies-virus-expressing-interleukin-18-exhibits-enhanced-immunogenicity-and-protection-in-mice
#14
Weiwei Gai, Wenwen Zheng, Chong Wang, Gary Wong, Yanyan Song, Xuexing Zheng
Several studies have shown that interleukin-18 (IL-18) plays an important role in both innate and adaptive immune responses. In this study, we investigated the pathogenicity and immunogenicity of recombinant rabies virus expressing IL-18 (rHEP-IL18). Experimental results showed that Institute of Cancer Research (ICR) mice that received a single intramuscular immunization with rHEP-IL18 elicited the highest titers of serum neutralizing antibodies and the strongest cell-mediated immune responses to prevent the development of rabies disease, compared with immunization with the parent virus HEP-Flury...
October 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/29207326/in-silico-prediction-of-potential-vaccine-candidates-on-capsid-protein-of-human-bocavirus-1
#15
Narayanan Kalyanaraman
Human bocavirus 1 (HBoV1) is a newly identified parvovirus that causes serious respiratory infection among children across the globe. Aim of the present study was to predict immunogenic residues located on the VP2 protein of HBoV1 towards development of epitope based vaccines. Several computational tools were employed to predict epitopes (bothT and B cell restricted) with stringent regulation for the improvement of confidence. After meticulous analysis, the peptide "TTPWTYFNFNQY" was identified as potential candidate for development of preventive vaccine...
December 2, 2017: Molecular Immunology
https://www.readbyqxmd.com/read/29206298/effects-of-poly-i-c-and-mf59-co-adjuvants-on-immunogenicity-and-efficacy-of-survivin-polypeptide-immunogen-against-melanoma
#16
Xiaoyu Jiang, Shanshan Guan, Yongbo Qiao, Xiao Li, Yan Xu, Lan Yang, Ziyu Kuai, Haihong Zhang, Yuhua Shi, Wei Kong, Yaming Shan, Hao Zhang
Malignant tumors pose a public health problem that jeopardizes human life and quality of living. At present, tumor vaccines in clinical research typically are aimed at stimulating the cellular immune response, while more effective vaccines should take into account the synergy between broad spectrum antibodies and high levels of cellular immunity. In this study, epitope peptides (68-81, 95-104, 80-88) of the tumor antigen survivin were chosen as immunogens and supplemented with poly(I:C) and/or MF59 adjuvant to evaluate the immune effects and anti-melanoma activities...
December 5, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29204145/molecular-signatures-of-immunity-and-immunogenicity-in-infection-and-vaccination
#17
REVIEW
Mariëlle C Haks, Barbara Bottazzi, Valentina Cecchinato, Corinne De Gregorio, Giuseppe Del Giudice, Stefan H E Kaufmann, Antonio Lanzavecchia, David J M Lewis, Jeroen Maertzdorf, Alberto Mantovani, Federica Sallusto, Marina Sironi, Mariagrazia Uguccioni, Tom H M Ottenhoff
Vaccinology aims to understand what factors drive vaccine-induced immunity and protection. For many vaccines, however, the mechanisms underlying immunity and protection remain incompletely characterized at best, and except for neutralizing antibodies induced by viral vaccines, few correlates of protection exist. Recent omics and systems biology big data platforms have yielded valuable insights in these areas, particularly for viral vaccines, but in the case of more complex vaccines against bacterial infectious diseases, understanding is fragmented and limited...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29203786/antigen-specific-oncolytic-mv-based-tumor-vaccines-through-presentation-of-selected-tumor-associated-antigens-on-infected-cells-or-virus-like-particles
#18
Stefan Hutzler, Stephanie Erbar, Robert A Jabulowsky, Jan R H Hanauer, Jürgen H Schnotz, Tim Beissert, Bianca S Bodmer, Regina Eberle, Klaus Boller, Thorsten Klamp, Ugur Sahin, Michael D Mühlebach
Recombinant vaccine strain-derived measles virus (MV) is clinically tested both as vaccine platform to protect against other pathogens and as oncolytic virus for tumor treatment. To investigate the potential synergism in anti-tumoral efficacy of oncolytic and vaccine properties, we chose Ovalbumin and an ideal tumor antigen, claudin-6, for pre-clinical proof of concept. To enhance immunogenicity, both antigens were presented by retroviral virus-like particle produced in situ during MV-infection. All recombinant MV revealed normal growths, genetic stability, and proper expression and presentation of both antigens...
December 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29203544/mapping-protective-regions-on-a-three-dimensional-model-of-the-moraxella-catarrhalis-vaccine-antigen-oligopeptide-permease-a
#19
Antonia C Perez, Antoinette Johnson, Ziqiang Chen, Gregory E Wilding, Michael G Malkowski, Timothy F Murphy
A vaccine against Moraxella catarrhalis will reduce tremendous morbidity, mortality, and financial burden by preventing otitis media in children and exacerbations of COPD in adults. Oligopeptide permease A (OppA) is a candidate vaccine antigen that is 1) a nutritional virulence factor expressed on the bacterial cell surface during infection, 2) widely conserved among strains, 3) highly immunogenic, and 4) a protective antigen based on its capacity to induce protective responses in immunized animals. In the present study, we show that the antibodies to OppA following vaccination mediate accelerated clearance in animals following pulmonary challenge...
December 4, 2017: Infection and Immunity
https://www.readbyqxmd.com/read/29203497/outer-membrane-vesicles-omv-based-and-proteomics-driven-antigen-selection-identifies-novel-factors-contributing-to-bordetella-pertussis-adhesion-to-epithelial-cells
#20
Gianmarco Gasperini, Massimiliano Biagini, Vanessa Arato, Claudia Gianfaldoni, Alessandro Vadi, Nathalie Norais, Giuliano Bensi, Isabel Delany, Mariagrazia Pizza, Beatrice Aricò, Rosanna Leuzzi
Despite high vaccination coverage world-wide, whooping cough, a highly contagious disease caused by Bordetella pertussis, is recently increasing in occurrence suggesting that novel vaccine formulations targeted at the prevention of colonization and transmission should be investigated. In order to identify new candidates for inclusion in the acellular formulation, we used spontaneously released outer membrane vesicles (OMV) as a potential source of key adhesins. The enrichment of Bvg+ OMV with adhesins and the ability of anti-OMV serum to inhibit the adhesion of B...
December 4, 2017: Molecular & Cellular Proteomics: MCP
keyword
keyword
99930
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"